Track topics on Twitter Track topics that are important to you
The primary objective of this study is to evaluate the effectiveness at 12 weeks of the OROS Methylphenidate for children with Attention Deficit Hyperactivity Disorder (ADHD). The treatment effectiveness will be evaluated based upon the response and remission rate which are evaluated using the K-ARS (Korean ADHD Rating Scale) and CGI (Clinical Global Impression). The secondary objectives of this study are to assess changes in overall functioning in activities of daily living and social functioning and to examine the impact of symptomatic remission on functional changes and a casual relationship between remission and functional changes after administering OROS Methylphenidate in children and adolescents with ADHD.
This is an open label (all people involved know the identity of the intervention), single arm, multicenter, prospective study evaluating the effectiveness of OROS (Osmotic-controlled Release Oral delivery System) methylphenidate for 12 weeks in treating children with Attention Deficit Hyperactivity Disorder (ADHD). Recently, the final aim of the treatment of ADHD goes beyond the stage of simple response to a drug and is being narrowed down to improvement in quality of life (QOL), day living (home and school life), functional recovery and the improvement of social relationships. Treatment effectiveness will be evaluated based upon response and remission rate. The secondary objectives are to examine how treatment with OROS Methylphenidate affects overall function and to determine the impact symptomatic remission has on changes in overall function. Adverse events will be reported during the study period. From the time point of starting the first procedure related to the study until the completion of all the study procedures, the investigator will follow up on any ongoing clinically significant abnormal results until stabilized or resolved. The study will assess safety and tolerability using the Symptom Rating Scale at every visit, clinical laboratory tests at visit 1, ECG at visit 1, vital signs/height/weight at first and last visit and physical exam at visit 1. The drug effect will be assessed by evaluating the improvement of subjects' ADHD symptoms before and after the treatment using the following standardized assessment surveys: Child Health and Illness Profile (CHIP), Korean ADHD Rating Scale (K-ARS), Clinical Global Impression of Severity (CGI-S) scale, Clinical Global Impression of Improvement (CGI-I) scale, Beck Depression Inventory (BDI), Parenting Stress Index (PSI), Comprehensive Attention Test (CAT) measures and academic performance. The patients will be on once daily study medication starting at 18 mg/day in children with less than 30 kg of body weight or at 27 mg/day in children with more than 30 kg. The dose is increased approximately every 7 days in 9 mg or 18 mg increments to 54 mg/day based on the clinical judgment of the investigator
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Attention Deficit Disorder With Hyperactivity
OROS methylphenidate hydrochloride
Janssen Korea, Ltd., Korea
Published on BioPortfolio: 2014-07-24T14:10:56-0400
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervou...
The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) ...
The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyp...
The purpose of the study is to investigate the clinical benefit of switching children with ADHD from immediate-release methylphenidate (IR-MPH) to OROS-methylphenidate under the correct do...
This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder.
PIEVSKY, M. A., and R. E. McGrath. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis…NEUROSCI BIOBEHAV REV 81(1) XXX-XXX, 2017.- This...
Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane...
The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulat...
Dermatillomania is characterized by excessive and repeated skin picking sufficient to damage cutaneous tissue, but with no underlying dermatological disease. The condition appears as an independent di...
To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-] TRODAT-1SPECT in a sample of treatment-naïve adolescents with Attentio...
A methylphenidate derivative, DOPAMINE UPTAKE INHIBITOR and CENTRAL NERVOUS SYSTEM STIMULANT that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-IV)
A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...
Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...